The pathogenesis of extrapancreatic tumor hypoglycemia has been related to the secretion of big insulin-like growth factor (IGF) II by the tumor. In 25 of 28 patients with this type of hypoglycemia we found 1.5-8-fold elevated serum levels of immunoreactive big (15-25 kD), but decreased levels of normal IGF II. After removal of the tumor, big IGF II disappeared and normal IGF II increased. Tumors contained elevated levels of IGF II, 65-80% in the big form. The insulin-like bioactivity of big IGF II and its affinity towards IGF-binding proteins (IGFBP)-2 and -3 are similar to those of normal IGF II, but two-to threefold higher on a molar basis. Big IGF II is mainly bound to the 50-kD IGFBP complex. The latter contains -10 times more of this peptide than in normal serum and displays three-to fourfold increased insulin-like bioactivity. The formation of the 150-kD IGFBP complex with "25I-recombinant human IGFBP-3 is impaired in tumor serum. This results in sequestration of IGFBP-3 and predominant association of big IGF II with IGFBP-2 and -3 in the 50-kD complex. Increased bioavailability of big IGF II in this complex due to unrestricted capillary passage and enhanced insulin bioactivity of this big IGF II pool provide a continuous increased insulin-like potential available to insulin and type 1 IGF receptors of insulin-sensitive tissues and thus may lead to sustained hypoglycemia. (J.
Introduction
Extrapancreatic tumor hypoglycemia (EPTH),' i.e., hypoglycemia associated with nonislet cell tumors, has for many years remained one of the "most baffling ofthe unsolved para-endocrine puzzles" (1) . Tumors of mesodermal, epithelial, and hematopoietic origin have been described to be associated with hypoglycemia (2) . The tumors are usually large and slowly growing. Hypoglycemia is a fasting hypoglycemia (2) with symptoms resulting from impaired supply of glucose to the brain, like headache, tiredness, confusion, amnesia, or even epileptic seizures. EPTH is characterized by three prominent metabolic features (3) (4) (5) : a block of hepatic glucose production due to inhibition of glycogenolysis and gluconeogenesis (2, 4) ; a block of lipolysis in adipose tissue resulting in low serum free fatty acid levels; and increased glucose assimilation, which may be partly due to increased glucose use by the tumor itself, but mainly by skeletal muscle (5) .
The pathogenesis of EPTH has long been a matter of debate. In 1974, Megyesi et al. (6) reported elevated serum levels of nonsuppressible insulin-like activity (NSILA-S) in five of seven patients with nonislet cell tumors. In an extended study of 52 patients with EPTH, 37% of the patients had elevated NSILA-S levels (7). Daughaday et al. (8) found elevated insulin-like growth factor (IGF) II in 10 of 14 sera from patients with tumor-related hypoglycemia. Thus, increased serum concentrations of an insulin-like substance, most likely IGF II, appeared to be responsible for the development of hypoglycemia in more than one-third of the patients. However, in contrast to these reports, we have never been able to detect significantly elevated serum levels of immunoreactive (ir) or receptorreactive (ir) IGF II in such patients nor did we find a decrease of IGF II after successful removal of the tumors (9, 10) . An important step to the solution of the puzzle was made in 1988: Daughaday et al. ( 11) described a patient with a leiomyosarcoma and recurrent hypoglycemia whose serum IGF II was normal both by IGF II RIA and radioreceptorassay, but in whose serum 70% ofthe total IGF II occurred as a higher molecular weight form, termed big IGF II. In addition, the tumor itself contained high concentrations of IGF II mRNA and of IGF II peptide. 77% ofthe IGF II in the tumor was present as a large molecule of -12-15 kD ( 1). The authors showed that after successful removal of the tumor the serum content of big IGF II had dropped to nearly zero. They concluded that the tumor was the main source of big IGF II in the serum of their patient and that the cause of the patient's recurrent hypoglycemia was IGF II produced by the tumor.
We have analyzed sera from 28 patients with EPTH for big IGF II and found elevated levels in 25 of these patients. Total irIGF II was not increased when determined by our standard method (9) . After successful operation, big IGF II disappeared from the serum, but total irIGF II did not decrease significantly.
We, therefore, addressed the question whether or not big IGF II can account for hypoglycemia in the presence ofnormal total IGF II levels. In a first approach we standardized the procedure for determination of 
Methods
Tumor sera and tumors. Sera from patients with EPTH were obtained from referring physicians from several European countries. All sera had been stored at -200C until used for analysis. The tumors had been classified as follows: three fibrosarcomas, two benign fibromas, two mesenchymal fibrous tumors, three mesotheliomas, four leiomyosarcomas, one histiocytoma, one hemangioendothelioma, one hemangiopericytoma, eight carcinomas (three carcinomas of the colon, one of the sigma, one adenocarcinoma of the stomach, one undifferentiated squamous carcinoma of the thorax, one undifferentiated carcinoma of the lung, one medullary thyroid carcinoma), and one gastrointestinal lymphoma. For two tumors we did not obtain a histological diagnosis.
Biogel P-60 Chromatography at acid pH. 0.5-1.0 ml of serum was gel-filtered on a Biogel P-60 column (Bio-Rad Laboratories, Richmond, CA; 2.2 x 70 cm, flow rate 12 ml/h) in 1 M acetic acid containing 20 mg/ 100 ml of HSA (Swiss Red Cross, Bern, Switzerland). The column had been calibrated with '25I-rhIGF I and '25I-rhIGF II and with unlabeled rhIGF II (rhIGF I and II were kindly provided by Drs. K. Muller and W. Marki, Ciba-Geigy AG, Basel, Switzerland). Four fractions each between fractions 44 and 1 19 were pooled, lyophilized, taken up in 2 ml 0.1 M NH4HCO3, and relyophilized. They were dissolved in 1 ml PBS, pH 7.4, containing 0.2 g/ 100 ml of HSA (RIA buffer) and assayed at two different dilutions in the IGF I and IGF II RIA (9) . Fractions 48-119 did not contain measurable amounts of IGFBPs as tested by Western ligand blotting with '25I-rhIGF II ( 12) .
For the determination of biological activity, 1.0-1.5 ml of normal or tumor serum was passed over the acidic Biogel P-60 column. 10 fractions each starting from fraction 25 were pooled, lyophilized, neutralized with 2 ml 0.1 M NH4HCO3, and relyophilized. Pools were dissolved in 1.0 ml of Krebs-Ringer-Hepes buffer, pH 7.4, and tested at two to three different dilutions (with the same buffer containing 0.2 g/ 100 ml of HSA) in the presence of 0.3 Mul of insulin antiserum (neutralizing capacity 0.4 mU) in the rat fat-cell assay ( 13) using porcine insulin and rhIGF II as standards. In another set of experiments, eight fractions each starting from fraction 40 were pooled, processed as above, dissolved in 0.7 ml of Krebs-Ringer-Hepes buffer, and tested in the fat-cell assay. IrIGF II-(9) and '25I-IGF II-displacing potencies using rhIGFBP-3 (reference 16; see below) were determined in the same pools.
Biogel P-60 chromatography at neutral pH. A Biogel P-60 column (O 2.2 x 70 cm, flow rate 10 ml/h) was equilibrated in 0.1 M NH4HCO3 containing 20 mg/ 100 ml of HSA and 20 mg/ 100 ml of NaN3 and was calibrated with different molecular weight markers (as indicated in Fig. 2 ) and with '25I-rhIGF I and '25I-rhIGF II.
For the determination ofthe apparent molecular mass ofbig IGF II, fractions 44-67 obtained by acidic Biogel P-60 chromatography of 1 ml oftumor serum (Fig. 1, peak I) were pooled, lyophilized, dissolved in 1 ml 0.1 M NH4HCO3, and passed over the neutral Biogel P-60 column. Similarly, pooled fractions 68-95 and 96-115 (Fig. 1 , peaks II and III) from the acidic Biogel P-60 column were rechromatographed at neutral pH. Every five fractions between fractions 40 and 85 were pooled, lyophilized, dissolved in 1 ml of RIA buffer, and tested at two different dilutions in the IGF II RIA (9) .
For determination of biological activity in neutral Biogel P-60 pools, 2 ml of normal or tumor serum was passed over the neutral Biogel P-60 column. Fractions 32-40, and then every five following fractions, were pooled, dialyzed against 0.1 M NH4HCO3 in dialysis tubing (Spectrapor; Spectrum Medical Industries, Inc., Los Angeles, CA; molecular weight cut-off, 3,500), lyophilized, dissolved in 1 ml 0.1 M NH4HCO3 containing 6 g/ 100 ml ofHSA, and tested at two or three different dilutions in the rat fat-cell assay ( 13) 10 ,000 g for 10 min at 40C. 1 ml of the supernate was chromatographed on the acidic Biogel P-60 column (see above).
Binding ofpartially purified big and normal IGF II to rhIGFBP-2 and rhIGFBP-3. Fractions 44-67 and 96-119 obtained by acidic Biogel P-60 chromatography of 10 x 0.5 ml of different tumor sera were pooled, lyophilized, dissolved in 1 ml H20, and rechromatographed on the acidic Biogel P-60 column. Fractions 48-67 containing big IGF II and fractions 96-119 containing normal IGF II were pooled, lyophilized, dissolved in RIA buffer, and standardized in the IGF II RIA (9) . The two preparations did not contain measurable amounts of IGFBPs or insulin. Their potencies to compete with 251I-rhIGF II for binding to rhIGFBP-2 and rhIGFBP-3 were compared with that ofrhIGF II in the protein-binding assay (16) . 0.4 ml of 0.1 M sodium phosphate buffer, pH 7.4, containing 0.8 mg of HSA and 5 ng ofrhIGFBP-2 (gift of Dr. J. Shuster, Chiron Corp., Emeryville CA) or 4.5 ng of rhIGFBP-3 (glycosylated, kindly provided by Drs. A. Sommer and C. A. Maack, BioGrowth, Richmond, CA), 50,000 cpm (-0.1 ng) 1251-rhIGF II, and increasing amounts of unlabeled rhIGF II or ofthe two IGF II preparations, was incubated for 2 h at room temperature. 20 min after the addition of 0.5 ml of a charcoal suspension (containing 2 g/ 100 ml of charcoal and 2 g/ 100 ml of HSA) at 4°C, the mixture was centrifuged (4°C, 15 min, 2,000 g), and 0.5 ml ofthe supernate was counted in a y counter.
The '251I-IGF II displacing potencies ofpooled fractions obtained by acidic Biogel P-60 chromatography of 1.5 ml of normal or tumor sera (see above) were determined by the same assay using rhIGFBP-3.
Distribution ofIGF I and II between the 150-and 50-kD IGFBP complexes. 2 ml of normal or tumor serum was passed over a Sephadex G-200 (Pharmacia LKB Biotechnology Inc., Uppsala, Sweden) column (2.2 x 70 cm, flow rate 10 ml/h) in Dulbecco's buffer, pH 7.4, containing 20 mg/ 100 ml of NaN3. Fractions 51-64, 65-71, and 72-84 corresponding to the elution ranges of the 150-and 50-kD IGFBP complexes (as determined from the radiochromatographic pattern of normal and tumor serum preequilibrated with 125I-rhIGF II and gel filtered over the same Sephadex G-200 column) and fractions eluting before (35) (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) (49) (50) and after (85-95 and 96-115) the two complexes (2 mg of HSA was added to fractions 80-115 to prevent adsorption of IGF to the tubes) were pooled, dialysed against 0.1 M NH4HCO3 in Spectrapor dialysis tubing (molecular weight cut-off, 3,500), lyophilized, and dissolved in 2 ml Krebs-Ringer-Hepes buffer, pH 7.4. The biological activity in each pool was determined in the presence of0.3 Ml of insulin antiserum (neutralizing capacity 0.4 mU) in the rat fat-cell assay (13). 1 ml of each pool was also passed over the acidic Biogel P-60 column described above. Fractions were pooled starting from fraction 44, pro-cessed as described above, and tested at two different dilutions in the IGF I and IGF II RIAs (9) .
Radiochromatography of sera with rhIGFBP-3. '251I-rhIGFBP-3 (glycosylated, specific radioactivity 160 ,uCi/Mg) was obtained from Anawa (Dubendorf, Switzerland). 0.2 ml serum was diluted with 0.3 ml Dulbecco's buffer, pH 7.4, and incubated with 3 X 105 cpm of '251I-rhIGFBP-3 and 25 ,u Trasylol (Bayer AG, Leverkusen, Germany)
for 24 h at 4°C. The incubation mixtures were passed over the neutral Sephadex G-200 column described above and fractions were counted in a y counter.
Results
Elution profiles ofIGF I and II on Biogel P-60 at acidic and neutral pH. When serum from a hypoglycemic patient with a leiomyosarcoma was gel filtered on the acidic Biogel P-60 column, peak I (big IGF II) became most prominent ( Fig. 1 B) . It eluted earlier than peak I of normal serum, indicating that its irIGF II has a somewhat higher molecular mass than in normal serum. Rechromatography of peak I from the tumor serum on a neutral Biogel P-60 column yields an apparent molecular mass of 20 kD (range, between 15 and 25 kD) (Fig. 2) .
After acidic Biogel P-60 chromatography, pooled fractions of the tumor serum were tested in the rat fat-cell assay for insulin-like bioactivity. Insulin and rhIGF II were used as stan- Radioactive fractions were counted in a y counter. For unlabeled rhIGF II and serum, four fractions each were pooled, processed as described in Methods, and assayed for irIGF I (A) and II (v). (B) Acidic gel filtration on Biogel P-60 of serum (0.5 ml) from a patient with a leiomyosarcoma causing hypoglycemia. Four fractions each were pooled, processed as described in Methods, and assayed for ir-IGF I (A) and II (o). For determination of biological activity, 1 ml serum of the same patient was chromatographed. 10 fractions each from 45 to 1 5 were pooled, processed as described in Methods, and tested in the rat fat-cell assay in the presence of insulin antiserum (0.3 ,ul, neutralizing capacity 0.4 mU). The height of the whole column represents rhIGF II RIA ng equivalents/pool x ml serum; hatched columns represent insulin equivalents in gU/pool x ml serum. dards. The bioactivity profile more or less parallels the profile of IGF II immunoreactivity ( Fig. 1 B) . When expressed in milliunits of insulin equivalents per milligrams of irIGF II, the pooled fractions 55-65 ( Fig. 1 B) corresponding to the peak of big IGF II display a similar specific insulin-like activity ( -360 mU/mg) as pooled fractions 105-115 ( Fig. I B) corresponding to 7.5-kD IGF II ('-300 mU/mg). Thus, on a molar basis (with an estimated molecular mass of20 kD for big IGF II) and assuming 100% cross-reactivity in the IGF II RIA, the insulinlike bioactivity ofbig IGF II would be enhanced approximately threefold compared with that of normal (7.5-kD) IGF II. In three other tumor sera the specific insulin-like bioactivity of pooled fractions 56-63 and 64-71 was enhanced two to threefold compared with pooled fractions 104-1 1 ( 17) is also reflected by the huge tissue level of IGF II mRNA compared with that ofadult normal liver or adipose tissue (Fig. 4) . The latter tissue is among those with the highest IGF II mRNA levels ofall adult normal human tissues tested so far (Peter, M. and J. Zapf, unpublished results). The Northern blot pattern of the tumors shows at least six different bands at approximately 7, 6, 4.5, 3.4 (3.0), 2, and 1.6 kb. On the basis ofthe elution profile ofirIGF II on Biogel P-60 at acidic pH ( Figs. 1 and 3) , we have analyzed 28 sera from patients with EPTH for big IGF II, IGF II dimer, and 7.5-kD IGF II (Fig. 5 ). According to this profile, irIGF II in fractions 44-67 has been defined as big IGF II, that in fractions 68-95 as IGF II dimer, and that in fractions 96-115 as 7.5-kD IGF 11. 25 of the 28 patients had 1.5-8-fold elevated big IGF II levels. 52.6±11.8% of total IGF II was accounted for by big IGF II, whereas in normal serum 10% occurs as a bigger form (Figs. 1  and 3 ). The three patients in whom big IGF II was not elevated had a gastrointestinal lymphoma, a hemangioendothelioma, and an adenocarcinoma of the colon. The percentage of big IGF II in their sera was < 10% oftotal. Their total IGF II levels determined by acidic Biogel P-60 chromatography were 844, 554, and 551 ng/ml compared with 920 ng/ml in normal serum. Only 4 of the 25 patients with elevated big IGF II had total IGF II levels > 1,000 ng/ml (1,062, 1,255, 1,328 and 1,369 ng/ml). In contrast to the elevation of the big form of IGF II, the IGF II dimer and the 7.5-kD IGF II were decreased in the 25 tumor sera compared with normal serum (Fig. 5) . This explains why total IGF II in most of these patients was within the normal range. In postoperative sera from four patients, big IGF II that had been elevated before removal of the tumor had dropped to or below normal, whereas the IGF II dimer and 7.5-kD IGF II had increased (Fig. 5, right) .
The affinities of big IGF II from tumor patients towards IGFBPs. The affinities for rhIGFBP-2 and rhIGFBP-3 of big and normal (7.5-kD) IGF II partially purified from 10 different tumor sera and standardized in the IGF II RIA were determined in a protein-binding assay ( 16 Fig. 7 and Table I Figure 7 . Molecular size distribution of big and normal (dimer and 7.5-kD) IGF II in normal serum and in serum of a patient with a leiomyosarcoma (same serum as in Fig. 1 B) tral Biogel P-60 chromatography (Fig. 8 ). These differences in biological activity are not due to differences in the content of large molecular weight NSILA, a still unidentified serum activity ( 18); after separation of IGF by acidic Biogel P-60 gel filtration the remaining large molecular weight NSILA is decreased rather than increased in the tumor serum pools (not shown). Thus, the increase of irIGF II in the native 50-kD binding protein complex of the tumor serum, which is exclusively acfrom a patient with a mesenchymal fibrous tumor ofthe pleura before and after operation (Table I) . Fig. 7 (Table I ) is similar to that of normal serum. After operation, big IGF II nearly disappeared from the 50-kD complex. The distribution of irIGF I between the two IGFBP complexes more or less parallels the distribution of irIGF II. Total IGF I is decreased in the preoperative serum and, like IGF II, is shifted towards the 50-kD complex.
Normal and tumor serum also differ with respect to their insulin-like bioactivities measured in the Sephadex G-200 pools of Fig. 7 : nonsuppressible insulin-like activity ofthe pool corresponding to the 50-kD binding protein complex of the tumor serum (fractions 72-84) is threefold higher than in normal serum (Table II) . The same results are obtained after neu- Figs. 1 B and 7) was chromatographed on the neutral Biogel P-60 column described in Fig. 2 A possible explanation for the overall increase of IGF II in the 50-kD complex of the tumor serum is provided by Fig. 9 . IGFBP-3 is sequestered from the 150-into the 50-kD binding protein complex. At the same time, IGFBP-2 in the 50-kD complex is increased. The reason for the sequestration of IGFBP-3 into the 50-kD binding protein complex is shown in Fig. 10 . When normal serum is preequilibrated with 25.IrhIGFBP-3 and chromatographed on the neutral Sephadex G-200 column, a major radioactive peak appears at the position ofthe 1 50-kD complex. In tumor serum this peak is lacking, and the radioactivity elutes at the position of "free" 125i-rhIGFBP-3. As estimated from the apparent molecular mass of 90 kD, 1251-rhIGFBP-3 obviously elutes as a dimer. Successful removal of the tumor completely restores the normal binding pattern (Fig. 10, middle and bottom) . The peak at fraction number 118 corresponds to 100% bed volume and probably represents free 12511 or '25I-labeled tyrosine resulting from degradation.
Discussion
Big IGF II, the key to the solution ofthe riddle ofextrapancreatic tumor hypoglycemia. The results of this study confirm and extend findings originally reported by Daughaday et al. (11 ) (19) in 1982 using acidic Biogel P-100 gel filtration. At acidic pH, Biogel P-60 does not only separate big from normal IGF II, but completely separates IGF I from 7.5-kD IGF II (reference 1 1; Fig. 1 A) despite their nearly identical molecular masses. Therefore, molecular mass estimations under these conditions can be misleading. A third IGF II species (Fig. 1, peak II) is detected with the acidic Biogel P-60 column. Most likely, it represents IGF II dimer that forms under acidic conditions because at neutral pH it elutes at the same position as unlabeled and radiolabeled 7.5-kD IGF II (Fig. 2) .
The finding that big IGF II disappears from the patients' sera after successful removal of the tumor (Figs. 3 and 5) , as previously also reported by Daughaday et al. ( 11), suggests that it is secreted by the tumor into the circulation. ( We have recently followed the time course of disappearance of big IGF II from serum after successful removal of a mesothelioma of the thorax that had caused severe hypoglycemia: big IGF II disappeared with a half-life of < 1 h. In the same patient, normal IGF II, which was decreased by 74% before the operation, rose with a half-life of 48 h.) The elevated IGF II mRNA levels in the three tumors (Fig. 4) and their increased content of IGF II, which is mainly accounted for by the big form (Fig. 3) , support this conclusion. Enhanced levels of IGF II mRNA in tumors associated with hypoglycemia as well as increased tissue levels of IGF II peptide with a high percentage ofbig IGF II have also been reported by others ( 11, (20) (21) (22) . The oma that had caused hypoglycemia were identical (Kiefer, M. C., and J. Zapf, unpublished results) to the cDNAs of normal IGF II and the IGF II variant cloned from a human liver cDNA library (23 The analysis of 28 sera from patients with EPTH does not only show that big IGF II is elevated in nearly all of these patients but also explains why we do not find elevated levels of total IGF II in most of the sera (Fig. 5) . The total content of IGF II in normal serum as determined by acidic Biogel P-60 chromatography was 920 ng/ml. In only 4 of the 28 analyzed sera was total IGF II above 1,000 ng/ml ( 1,062-1,369 ng/ml).
The elevation of big IGF IIin the tumor sera is compensated by a decrease of "normal" IGF II (dimer and 7.5-kD IGF II) (Fig.  5) . On the other hand, when big IGF II drops after removal of the tumor, normal IGF II rises (Fig. 5) (27) . Biological activity and affinities of partially purified big IGF IIfor serum IGFBPs. In view of the normal serum IGF II levels found by RIA and radioreceptorassay in nearly all of our patients with EPTH (9, 10) and in more than half of the patients reported by Gorden et al. ( 7 ) , the question arises whether the elevation ofbig IGF II in the presence ofa normal total IGF II serum level can account for hypoglycemia. Partially purified big IGF II stimulates glucose metabolism in rat fat cells (Fig. 1  B) . Calculated on a molar basis, its biological insulin-like activity is two-to threefold higher than that of normal IGF II. Since IGFs stimulate glucose metabolism in rat fat cells via the insulin receptor (28, 29) , big IGF II may activate the insulin receptor more efficiently than normal IGF II. However, this is not yet sufficient to explain hypoglycemia in tumor patients: in normal serum > 98% of total IGF II is bound to IGFBPs (30) , and 70-80% is associated with a 1 50-kD IGFBP complex (31 ) . The bioavailability ofthis latter IGF pool is largely restricted by the capillary barrier (31, 32 The distribution ofbig IGF II between the 150-and 50-kD IGFBP complexes and its bioavailability. Besides the IGF pool associated with the 1 50-kD complex, two other IGF pools exist in serum; 20-30% ofthe total IGF ofnormal serum resides in a 50-kD IGFBP complex (31 ) . This IGF pool disappears from the circulation with a half-life of 20 to 30 min (30) and, therefore, has a high turnover rate. The 50-kD binding protein complex of normal serum contains mainly IGFBP-2 and relatively little IGFBP-3 (12, 33) . This complex can cross the capillary barrier (32) and may thus render its IGF bioavailable to tissues. A third IGF pool consists of free IGF in equilibrium with the two IGFBP complexes. Free IGF is readily bioavailable (34), but < 2% of total IGF II in normal serum occurs in the free form (30) . Increased bioavailability ofbig IGF II would be achieved by its predominant association with the 50-kD binding protein complex. This would lead to increased delivery of big IGF II to tissue receptors.
Previous studies by Daughaday and Kapadia (35) and by our own group ( 12) have shown that the IGF II content of the 50-kD complex of tumor sera is increased. In addition, the 50-kD complex of tumor sera contains increased amounts of IGFBP-2 and IGFBP-3 (12) , whereas the IGFBP-3 content of the 150-kD complex is reduced (reference 12, and Fig. 9 ). The three patients in Daughaday's and Kapadia's study (35) showed a lack of the 1 50-kD binding protein complex, which was reversed after operation. We have so far not seen a complete lack of the 150-kD complex in tumor sera, but usually find it reduced (Fig. 7 B) , probably because of decreased production of the acid-labile subunit (see below). As a consequence, IGFBP-3 is sequestered into the 50-kD complex (Fig.  9) . The latter also contains increased amounts of IGFBP-2 (reference 12; Fig. 9 ). These changes result in an apparent shift of IGF II from the 150-into the 50-kD complex with a two-to fourfold increase of its IGF II content (reference 12; Fig. 7 , Table I ) and of its insulin-like activity (Fig. 8 , Table II ). The increase of IGF II in the 50-kD complex is exclusively accounted for by big IGF II (Fig. 7, Table I ). Hence, the turnover and bioavailability of big IGF II is considerably enhanced.
The differences between the radiochromatographic patterns ofnormal and tumor serum (Fig. 7, A and B Figure 11 . Suggested mechanism of the development of extrapancreatic tumor hypoglycemia.
( 1 1, 20, 21, 37-39) , and, in the case of big IGF II excess, a decrease of endogenous IGF I and of normal IGF II. The latter two changes probably result from the displacement of IGF I and IGF II from IGFBPs by big IGF II as well as from the suppression of growth hormone secretion. Although IGF II is less dependent on growth hormone than IGF I, its level is decreased in growth hormone-deficient states (9) . Suppression of growth hormone secretion leads to a diminished production of IGFBP-3 (33) and of the acid-labile subunit of the 1 50-kD binding protein complex (36) . Baxter and Daughaday (36) found low normal RIA-IGFBP-3 levels in patients with EPTH. It is possible that the RIA also recognizes degraded IGFBP-3, which might result from increased protease activity in the sera of tumor patients. However, we have not detected significant amounts of truncated binding protein-3 as an indicator of increased protease activity in our patients' sera. As tested by Western ligand blotting, the amount of binding protein-3 in our patients was variable ranging from near normal to significantly decreased levels. Decreased acid-labile subunit levels probably account for the reduction or disappearance of the 150-kD complex and thus for the sequestration of IGFBP-3 into the 50-kD complex. Its increased content of IGFBP-2 due to the suppression of insulin and growth hormone secretion ( 12) and of IGFBP-3 goes along with the predominant association with big IGF II. Because ofthe short half-life ofthe 50-kD IGF pool and its high turnover rate (30) , increased amounts of big IGF II reach the interstitial space and become bioavailable to insulin target tissues. This then leads to stimulation ofglucose consumption in skeletal muscle via the insulin and/or the type 1 IGF receptor and to suppression of hepatic glucose production and oflipolysis in adipose tissue via the insulin receptor and results in sustained hypoglycemia. Low serum free fatty acid levels resulting from inhibition oflipolysis may contribute to enhanced peripheral glucose consumption via the Randle cycle (40) . In addition, upregulation of insulin receptors may occur in the presence of low serum insulin levels and thus cause enhanced insulin sensitivity. Indeed, Stuart et al. (41) found a three-to fivefold increase in the insulin receptor number on mononuclear cells and on liver and muscle plasma membranes of a patient with hypoglycemia associated with a colon carcinoma metastatic to the liver. However, big IGF II in the serum and the tumor of this patient was not reported. Within the same context, Barzilai et al. (42) described a diabetic patient with a hepatoma subsequent to hemochromatosis and cirrhosis who lost dependence on insulin and experienced episodes of hypoglycemia. The insulin dose-response curve in this patient as determined by euglycemic clamp technique was shifted to the left, and steady state glucose consumption was 50% higher than in normal control subjects. Total IGF I and IGF II in the patient's serum were not elevated, but again, big IGF II was not assessed.
Finally, it is easily conceivable that big IGF II secreted by the tumor stimulates glucose uptake by the tumor in an auto/ paracrine fashion. Since the tumor mass not infrequently reaches 2 2-3 kg, the latter mechanism may come into play although it has been calculated that it would not be sufficient to fully account for hypoglycemia in this syndrome (for review see reference 1). 
